New single-shot drug may protect young cancer patients from dangerous infections during chemo
NCT ID NCT06926751
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This study tests whether a new drug called Telpegfilgrastim, given as a single shot, works better than the standard daily drug Filgrastim at preventing dangerously low white blood cell counts (neutropenia) in children and teens aged 6 to 24 with solid tumors. About 132 participants will receive either the new or standard drug after each chemotherapy cycle. The main goal is to see if the new drug reduces fevers and infections during the first cycle.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY INDUCED NEUTROPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.